Indian generic drug makers Dr. Reddy’s Laboratories have agreed to obtain a Cardiovascular Cidmus brand from Global Pharmaceutical Giant Novartis AG for $ 61 million (around Rs 463 Crore).

It came a few weeks after Dr. Reddy signed an exclusive sales and distribution agreement with a global health giant based in Switzerland to buy the last set of drugs that cover the range of vovans, calcium range, and methergine.

Under the latest agreement, Dr. Reddy will be assigned and transferred the Cidmus trademark in India from Novartis AG. Cidmus saw sales of Rs 136.4 Crore in India for the last twelve months ending in February 2022.

In a statement on April 1, Dr. Reddy said the cidmus brand would be attached to the pharmaceutical composition consisting of a combination of Valsartan and Sacubitril (currently under the novartist patent) which is indicated for heart failure patients with a decrease in the ejection fraction.

Hyderabad’s center-based drug maker said it would be seen utilizing a wide base to engage with health professionals and significantly increased product range in and outside Metros to market Tier-i and Level II in India through a network of marketing and strong distribution to maximize access to patients in India.

Dr. Reddy said that the prevalence of cardiovascular disease, this acquisition would make it possible to make a trusted drug portfolio available to patients in India and that Cyidmus will be a strong addition to the portfolio in the cardiovascular segment in addition to stamlo, stamlo beta, reclide-xr and recleget -XR.

Furthermore, Dr. Reddy said the acquisition of Cidmus from Novartis AG would take him closer to his ambition to enter the top 10 heart players in the Indian pharmaceutical market and strengthen his presence in chronic space in India.